DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Early Stage / Preclinical Research
Current multiple sclerosis therapies primarily reduce inflammatory activity but do not directly repair existing myelin damage. Researchers identified CN045 through a 20,000-compound screening program and evaluated its effects on oligodendrocyte maturation and remyelination.
Clinical Considerations
- CN045 increased maturation of oligodendrocyte progenitor cells into myelin-producing oligodendrocytes in human cell models.
- Treated cells formed myelin-like coverings around synthetic nerve fiber analogs, demonstrating functional maturation.
- The compound produced modest remyelination in a mouse model of myelin loss.
- Investigators reported brain penetration and low toxicity, but rapid metabolic breakdown remains a development challenge.
Practice Applications
- Recognize remyelination as an emerging area of investigation in MS.
- Interpret CN045 findings as preclinical evidence rather than therapeutic efficacy.
- Monitor development of remyelination-focused drug programs.
- Avoid equating animal remyelination models with clinical neurological recovery.
